[
  {
    "ts": null,
    "headline": "Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results",
    "summary": "ISRG posts strong preliminary Q4 and full-year 2025 revenue growth, but shares dip as investors weigh procedure trends, margins and outlook.",
    "url": "https://finnhub.io/api/news?id=df8455018ab6b57a318ed582a92a6254e239e3521cd39badd50633628505a584",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768585560,
      "headline": "Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results",
      "id": 138155412,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "ISRG posts strong preliminary Q4 and full-year 2025 revenue growth, but shares dip as investors weigh procedure trends, margins and outlook.",
      "url": "https://finnhub.io/api/news?id=df8455018ab6b57a318ed582a92a6254e239e3521cd39badd50633628505a584"
    }
  },
  {
    "ts": null,
    "headline": "DexCom Stock Declines Following Strong Preliminary Q4 Results",
    "summary": "DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.",
    "url": "https://finnhub.io/api/news?id=e4dff2a4e85e869943dbd884e690f8072fae0a8a9033d0b41eed3458dda67ef8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768585320,
      "headline": "DexCom Stock Declines Following Strong Preliminary Q4 Results",
      "id": 138155443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.",
      "url": "https://finnhub.io/api/news?id=e4dff2a4e85e869943dbd884e690f8072fae0a8a9033d0b41eed3458dda67ef8"
    }
  },
  {
    "ts": null,
    "headline": "This is Why Wall Street Firms are Bullish on Boston Scientific Corporation (BSX)",
    "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the best blue-chip stocks to buy for 2026. Boston Scientific Corporation (NYSE:BSX) said on January 12 that it has agreed to acquire Valencia Technologies, maker of the FDA-approved eCoin System for urge urinary incontinence. The coin-sized implant, placed near the ankle, uses tibial nerve stimulation to help control [因",
    "url": "https://finnhub.io/api/news?id=059643a8810781cb50205cfcec15f5c13efe4514161135c775ba0f4f6b95e36f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768583545,
      "headline": "This is Why Wall Street Firms are Bullish on Boston Scientific Corporation (BSX)",
      "id": 138154096,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the best blue-chip stocks to buy for 2026. Boston Scientific Corporation (NYSE:BSX) said on January 12 that it has agreed to acquire Valencia Technologies, maker of the FDA-approved eCoin System for urge urinary incontinence. The coin-sized implant, placed near the ankle, uses tibial nerve stimulation to help control [因",
      "url": "https://finnhub.io/api/news?id=059643a8810781cb50205cfcec15f5c13efe4514161135c775ba0f4f6b95e36f"
    }
  },
  {
    "ts": null,
    "headline": "Penumbra (PEN) Climbs to All-Time High on $14.5-Billion Merger",
    "summary": "We recently published 10 Stock With Eye-Popping Gains; 5 Are on Fresh Highs. Penumbra Inc. (NYSE:PEN) was one of the top performers on Thursday. Penumbra soared to a new all-time high on Thursday, as investors snapped up shares following announcements that it is set to be acquired by Boston Scientific Corporation for $14.5 billion. At [因",
    "url": "https://finnhub.io/api/news?id=373589957616f70faf82caa55a68914732113dcf886a93653990d66cbd07335a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768581228,
      "headline": "Penumbra (PEN) Climbs to All-Time High on $14.5-Billion Merger",
      "id": 138154097,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "We recently published 10 Stock With Eye-Popping Gains; 5 Are on Fresh Highs. Penumbra Inc. (NYSE:PEN) was one of the top performers on Thursday. Penumbra soared to a new all-time high on Thursday, as investors snapped up shares following announcements that it is set to be acquired by Boston Scientific Corporation for $14.5 billion. At [因",
      "url": "https://finnhub.io/api/news?id=373589957616f70faf82caa55a68914732113dcf886a93653990d66cbd07335a"
    }
  },
  {
    "ts": null,
    "headline": "Down 6.3% in 4 Weeks, Here's Why Boston Scientific (BSX) Looks Ripe for a Turnaround",
    "summary": "Boston Scientific (BSX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.",
    "url": "https://finnhub.io/api/news?id=800b500cda55a149b340cf4edd17d04604b778e10e9419e7a8ccf31f589b9301",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768574102,
      "headline": "Down 6.3% in 4 Weeks, Here's Why Boston Scientific (BSX) Looks Ripe for a Turnaround",
      "id": 138154098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific (BSX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.",
      "url": "https://finnhub.io/api/news?id=800b500cda55a149b340cf4edd17d04604b778e10e9419e7a8ccf31f589b9301"
    }
  },
  {
    "ts": null,
    "headline": "Hologic Leads Campaign to Emphasize Routine Cervical Cancer Screening",
    "summary": "HOLX launches Ultimate Defense, a new U.S. campaign that urges routine Pap + HPV screening to boost awareness and help curb rising underscreening.",
    "url": "https://finnhub.io/api/news?id=da4c12e45fa90d4eb76d892559beff66149dde4bbc584c1fc9d741597c31f64a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768565880,
      "headline": "Hologic Leads Campaign to Emphasize Routine Cervical Cancer Screening",
      "id": 138151782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "HOLX launches Ultimate Defense, a new U.S. campaign that urges routine Pap + HPV screening to boost awareness and help curb rising underscreening.",
      "url": "https://finnhub.io/api/news?id=da4c12e45fa90d4eb76d892559beff66149dde4bbc584c1fc9d741597c31f64a"
    }
  },
  {
    "ts": null,
    "headline": "Penumbra (PEN) Moves 11.8% Higher: Will This Strength Last?",
    "summary": "Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
    "url": "https://finnhub.io/api/news?id=5b3f5947a34dda3fc583390e729514bd93509fc2d675000650145400e81199c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768560360,
      "headline": "Penumbra (PEN) Moves 11.8% Higher: Will This Strength Last?",
      "id": 138151783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.",
      "url": "https://finnhub.io/api/news?id=5b3f5947a34dda3fc583390e729514bd93509fc2d675000650145400e81199c4"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific: Adding Another Growth Engine With Penumbra",
    "summary": "Boston Scientific stock outlook: 20%+ sales growth, 15%+ organic momentum, and M&A-driven expansion (incl. $15B Penumbra deal).",
    "url": "https://finnhub.io/api/news?id=20946224eeaf82db0ad6602fd3955d293be4b2d5625e6e530fd2b25600e031c6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768548889,
      "headline": "Boston Scientific: Adding Another Growth Engine With Penumbra",
      "id": 138151294,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1182574929/image_1182574929.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Boston Scientific stock outlook: 20%+ sales growth, 15%+ organic momentum, and M&A-driven expansion (incl. $15B Penumbra deal).",
      "url": "https://finnhub.io/api/news?id=20946224eeaf82db0ad6602fd3955d293be4b2d5625e6e530fd2b25600e031c6"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific's Bet On Penumbra Isn't To My Liking",
    "summary": "Boston Scientific will acquire Penumbra for $14.5B in cash, gaining thrombectomy exposure while adding $10.7B in net debt. Learn more on BSX and PEN stocks here.",
    "url": "https://finnhub.io/api/news?id=3e52c7775eaa18b5cfdffc2a1d283ffdb8a2bef54c855e8917dc13e87803528d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768531431,
      "headline": "Boston Scientific's Bet On Penumbra Isn't To My Liking",
      "id": 138148619,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1365592578/image_1365592578.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Boston Scientific will acquire Penumbra for $14.5B in cash, gaining thrombectomy exposure while adding $10.7B in net debt. Learn more on BSX and PEN stocks here.",
      "url": "https://finnhub.io/api/news?id=3e52c7775eaa18b5cfdffc2a1d283ffdb8a2bef54c855e8917dc13e87803528d"
    }
  }
]